UK Community Advisory Board (UK-CAB)

CAB 54 – NHS HIV drug approval process, CROI 2015 feedback

Friday 17 April 2015


09.15-10.00 Registration, refreshments and expenses
10.00-10.15 Welcome and  introductions
10.15-11.15 Clinical Priorities Advisory Group (CPAG)
Sir Nick Partridge
11.15-11.30 Break
11.30-12.00 How to respond to a CRG consultation
Damian Kelly
12.00-13.00 Medication approval process in England and Scotland
Garry Brough, Simon Collins and Jackie Morton
13.00-14.30 Lunch: Strada restaurant, 15-17 The Brunswick Centre, WC1N 1AF.
14.30-15.45 Feedback from 22nd Conference on Retroviruses and OIs (CROI), February 2015
Simon Collins
15.45-16.00 Break
16.00-16.30 BHIVA Treatment Guidelines: community consultation
Roy Trevelion
16.30-16.45 Member feedback, UK-CAB AOB
16.45 Meeting close

Presentations from this meeting

Clinical Priorities Advisory Group (CPAG) Prioritisation Framework 
CROI 2015 feedback
BHIVA Treatment Guidelines Community Consultation 

Background reading

This is a brief summary of important studies and new from CROI. This includes PrEP, new ARVs, drug interactions and a UK case of HIV remission. Each study has a hyperlink to a more detailed report in HTB.  (PDF – 60 Kb)

This is a consultation on the prioritisation process for specialised services in the NHS:

NHS England HIV specific policies under consultation – PDF files:

Clinical Commissioning Policy: Treatment as Prevention (TasP) in HIV infected adults

Clinical Commissioning Policy: Use of cobicistat (Tybost®) as a booster in treatment of HIV positive adults and adolescents

Clinical Commissioning Policy: Stribild® for the treatment of HIV-1 infection in adults

The Scottish Medicine Council’s guidance on making submissions and approval process.

General info about public involvement:

Scottish Medicine Council guidance for patient groups submitting:

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.